Product Description
Becatecarin (rebeccamaycin analogue-RA) is an anti-tumor antibiotic with inhibitory activity against both topoisomerase II and I as well as DNA intercalating properties. (Sourced from: https://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.19060)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location: Europe
Company Founding Year: 1976
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Biliary Tract Cancer
Phase 2: Small Cell Lung Cancer|Male Breast Cancer|Cholangiocarcinoma|Sarcoma|Colorectal Cancer|Primary Central Nervous System Lymphoma|Retinoblastoma|Brain Stem Cancer|Gallbladder Cancer|Ovarian Cancer|Non-Small-Cell Lung Cancer|Liver Cancer|Bile Duct Cancer|Kidney Cancer|Neuroblastoma|Renal Cell Carcinoma
Phase 1: Precursor Cell Lymphoblastic Leukemia-Lymphoma|Anemia, Refractory, with Excess of Blasts|Preleukemia|Chronic Myelomonocytic Leukemia|Anemia, Aplastic|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Lymphoid Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Blast Crisis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00087204 |
NCI-2012-02609 | P1 |
Completed |
Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Lymphoid Leukemia|Acute Lymphoid Leukemia|Preleukemia|Blast Crisis|Chronic Myeloid Leukemia|Anemia, Aplastic|Chronic Myelomonocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Myelodysplastic Syndrome |
2007-01-01 |
2019-03-21 |
Treatments |
|
NCT00084487 |
NCI-2012-02587 | P2 |
Terminated |
Small Cell Lung Cancer |
2008-04-01 |
2019-03-21 |
Treatments |
|
NCT00003737 |
CDR0000066852 | P2 |
Completed |
Neuroblastoma |
2006-09-01 |
2019-03-21 |
Treatments |
|
NCT00006102 |
NCI-2012-01851 | P2 |
Completed |
Brain Stem Cancer|Retinoblastoma|Neuroblastoma|Primary Central Nervous System Lymphoma|Sarcoma |
2006-06-01 |
2020-10-26 |
Treatments |
|
NCT00005817 |
NCI-2013-00031 | P2 |
Completed |
Male Breast Cancer |
2006-05-01 |
2019-03-21 |
Treatments |
|
NCT00005997 |
CWRU2299 | P2 |
Terminated |
Gallbladder Cancer|Bile Duct Cancer|Cholangiocarcinoma|Liver Cancer |
2005-04-01 |
2019-03-21 |
Treatments |
|
NCT00005027 |
CDR0000067548 | P2 |
Completed |
Kidney Cancer|Renal Cell Carcinoma |
2005-03-01 |
2019-03-21 |
||
NCT00006017 |
CWRU1599 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2003-07-01 |
2019-03-21 |
Treatments |
|
NCT00005085 |
IMT Codes 23988, 23989, 23993 | P2 |
Completed |
Colorectal Cancer |
2002-06-01 |
2019-03-21 |
||
NCT00006262 |
NCI 00G1 | P2 |
Terminated |
Ovarian Cancer |
2001-09-01 |
2019-03-21 |
Treatments |
|
NCT00090025 |
XL119-001 | P3 |
Terminated |
Biliary Tract Cancer |
2006-11-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|